1664OA randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial

1664OA randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 29; no. suppl_8
Main Authors: Pujol, J-L, Greillier, L, Audigier Valette, C, Moro-Sibilot, D, Uwer, L, Hureaux, J, Thiberville, L, Carmier, D, Madelaine, J, Otto, J, Gounant, V, Merle, P, Mourlanette, P, Molinier, O, Renault, P A, Mazieres, J, Antoine, M, Langlais, A, Morin, F, Souquet, P-J
Format: Journal Article
Language:English
Published: Oxford University Press 01-10-2018
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy298